IL165323A0 - Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments - Google Patents
Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatmentsInfo
- Publication number
- IL165323A0 IL165323A0 IL16532303A IL16532303A IL165323A0 IL 165323 A0 IL165323 A0 IL 165323A0 IL 16532303 A IL16532303 A IL 16532303A IL 16532303 A IL16532303 A IL 16532303A IL 165323 A0 IL165323 A0 IL 165323A0
- Authority
- IL
- Israel
- Prior art keywords
- dna
- checkpoint
- compounds
- damage
- ycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/36—Esters of dithiocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38693002P | 2002-06-06 | 2002-06-06 | |
| PCT/IB2003/003164 WO2003104181A2 (en) | 2002-06-06 | 2003-06-06 | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165323A0 true IL165323A0 (en) | 2006-01-15 |
Family
ID=29736236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16532303A IL165323A0 (en) | 2002-06-06 | 2003-06-06 | Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| IL165323A IL165323A (en) | 2002-06-06 | 2004-11-22 | Compounds that eliminate a 2 g checkpoint in the cell cycle that is attracted by DNA damage And / or aiding anti-cancer activity of DNA-damaging treatments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165323A IL165323A (en) | 2002-06-06 | 2004-11-22 | Compounds that eliminate a 2 g checkpoint in the cell cycle that is attracted by DNA damage And / or aiding anti-cancer activity of DNA-damaging treatments |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7030111B2 (de) |
| EP (1) | EP1511713B8 (de) |
| JP (2) | JP4919598B2 (de) |
| KR (1) | KR100984951B1 (de) |
| CN (1) | CN100577631C (de) |
| AT (1) | ATE520653T1 (de) |
| AU (1) | AU2003247044B8 (de) |
| CA (1) | CA2487388C (de) |
| ES (1) | ES2369534T3 (de) |
| IL (2) | IL165323A0 (de) |
| NO (1) | NO20045556L (de) |
| WO (1) | WO2003104181A2 (de) |
| ZA (1) | ZA200409650B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4919598B2 (ja) * | 2002-06-06 | 2012-04-18 | 株式会社 キャンバス | Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物 |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
| WO2007097010A1 (ja) * | 2006-02-21 | 2007-08-30 | The Kitasato Institute | Ｆｋｉ−２３４２物質およびその製造法 |
| CA2679955A1 (en) * | 2006-10-13 | 2008-05-29 | Reliance Life Sciences Pvt. Ltd. | Novel chemotherapeutic agents against inflammation and cancer |
| EP2152692B9 (de) * | 2007-04-11 | 2020-03-25 | Canbas Co. Ltd. | Verbindungen mit krebshemmender wirkung |
| EP3578974A1 (de) * | 2018-06-08 | 2019-12-11 | Novagray | Bleomycin zur nachahmung der wirkung ionisierender strahlung auf t-zellen |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913483A (en) * | 1958-05-08 | 1959-11-17 | Dow Chemical Co | Lower alkylphenyl 2, 4-dichloro-benzoates |
| DE2049865A1 (en) * | 1970-10-10 | 1972-04-13 | Dynamit Nobel Ag, 5210 Troisdorf | Aromatic acid aryl esters - prepd from aromatic trichloromethyl cpds phenols and water |
| US4394389A (en) * | 1979-03-01 | 1983-07-19 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors |
| JPS56110777A (en) * | 1980-02-07 | 1981-09-02 | Chisso Corp | Ester derivative of 4-fluorobenzoic acid |
| US4612386A (en) * | 1980-09-16 | 1986-09-16 | The Dow Chemical Company | Process for making esters |
| JPS58188838A (ja) * | 1982-04-27 | 1983-11-04 | Chisso Corp | ４−（４′−フルオロベンゾイルオキシ）フエノ−ルのエステル誘導体 |
| US4934389A (en) * | 1988-12-06 | 1990-06-19 | Pettiford William L | Dental floss dispenser |
| FR2649977B1 (fr) | 1989-07-18 | 1991-10-04 | Cird | Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| JP2696434B2 (ja) * | 1991-01-23 | 1998-01-14 | 富士写真フイルム株式会社 | 画像形成方法 |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US6017958A (en) | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| CA2216559A1 (en) * | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
| ATE251624T1 (de) | 1998-03-13 | 2003-10-15 | Univ British Columbia | Granulatimide-derivate zur behandlung von krebs |
| JP2002507567A (ja) * | 1998-03-25 | 2002-03-12 | ラージ スケール バイオロジー コーポレイション | 血管形成を阻害するための安息香酸誘導体 |
| ES2239037T3 (es) | 1999-09-22 | 2005-09-16 | Canbas Co., Ltd. | Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna. |
| US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| CN101092455B (zh) | 2002-01-17 | 2012-07-04 | 坎巴斯有限公司 | 具有抗增殖活性和/或可增强核酸损伤剂或治疗的效果的肽和肽模拟物 |
| US7202244B2 (en) * | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP4919598B2 (ja) * | 2002-06-06 | 2012-04-18 | 株式会社 キャンバス | Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物 |
| US6881573B2 (en) * | 2003-09-12 | 2005-04-19 | Allan L. Louderback | Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
-
2003
- 2003-06-06 JP JP2004511251A patent/JP4919598B2/ja not_active Expired - Fee Related
- 2003-06-06 US US10/457,029 patent/US7030111B2/en not_active Expired - Fee Related
- 2003-06-06 AU AU2003247044A patent/AU2003247044B8/en not_active Ceased
- 2003-06-06 WO PCT/IB2003/003164 patent/WO2003104181A2/en active Application Filing
- 2003-06-06 CA CA2487388A patent/CA2487388C/en not_active Expired - Fee Related
- 2003-06-06 CN CN03818476A patent/CN100577631C/zh not_active Expired - Fee Related
- 2003-06-06 IL IL16532303A patent/IL165323A0/xx unknown
- 2003-06-06 ES ES03757173T patent/ES2369534T3/es not_active Expired - Lifetime
- 2003-06-06 AT AT03757173T patent/ATE520653T1/de not_active IP Right Cessation
- 2003-06-06 KR KR1020047019826A patent/KR100984951B1/ko not_active IP Right Cessation
- 2003-06-06 EP EP03757173A patent/EP1511713B8/de not_active Expired - Lifetime
-
2004
- 2004-11-22 IL IL165323A patent/IL165323A/en not_active IP Right Cessation
- 2004-11-29 ZA ZA200409650A patent/ZA200409650B/en unknown
- 2004-12-20 NO NO20045556A patent/NO20045556L/no unknown
-
2006
- 2006-01-17 US US11/334,160 patent/US7407985B2/en not_active Expired - Lifetime
-
2008
- 2008-06-02 US US12/131,639 patent/US7629364B2/en not_active Expired - Fee Related
- 2008-06-02 US US12/131,564 patent/US7652042B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 JP JP2010099281A patent/JP2010168398A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1511713B8 (de) | 2012-02-08 |
| KR20050019730A (ko) | 2005-03-03 |
| JP4919598B2 (ja) | 2012-04-18 |
| US7629364B2 (en) | 2009-12-08 |
| US7030111B2 (en) | 2006-04-18 |
| NO20045556L (no) | 2005-03-04 |
| AU2003247044B8 (en) | 2009-04-09 |
| WO2003104181A3 (en) | 2004-07-29 |
| CN1671644A (zh) | 2005-09-21 |
| JP2005528457A (ja) | 2005-09-22 |
| ATE520653T1 (de) | 2011-09-15 |
| ZA200409650B (en) | 2006-09-27 |
| EP1511713B1 (de) | 2011-08-17 |
| IL165323A (en) | 2015-05-31 |
| CA2487388C (en) | 2011-05-10 |
| US20080293137A1 (en) | 2008-11-27 |
| US20040198727A1 (en) | 2004-10-07 |
| AU2003247044B2 (en) | 2009-03-26 |
| KR100984951B1 (ko) | 2010-10-01 |
| ES2369534T3 (es) | 2011-12-01 |
| US7652042B2 (en) | 2010-01-26 |
| CN100577631C (zh) | 2010-01-06 |
| AU2003247044A1 (en) | 2003-12-22 |
| WO2003104181A2 (en) | 2003-12-18 |
| CA2487388A1 (en) | 2003-12-18 |
| US20080227827A1 (en) | 2008-09-18 |
| EP1511713A2 (de) | 2005-03-09 |
| US7407985B2 (en) | 2008-08-05 |
| US20060122269A1 (en) | 2006-06-08 |
| JP2010168398A (ja) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY141119A (en) | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | |
| MY137053A (en) | Pyrimidine derivatives and their use as cb2 modulators | |
| MX2007004551A (es) | Compuestos tiadiazol y metodos de uso. | |
| MXPA06000933A (es) | Compuestos de aminopirazol y uso como inhibidores de chk1. | |
| GB0222495D0 (en) | Compounds | |
| NO20081349L (no) | Pyrrolopyrimidinderivater som Syk-inhibitorer | |
| DE10393306D2 (de) | Mesenchymale Stammzellen des Haarfollikels und deren Verwendung | |
| WO2005030121A3 (en) | Compounds, compositions and methods | |
| NO20060518L (no) | Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| MX2020009403A (es) | Compuestos con actividad anticancer. | |
| UA92503C2 (ru) | Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств | |
| NO20061194L (no) | Mitotiske kinesininbibitorer | |
| ATE506953T1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| MXPA05013075A (es) | Inhibidores de p-38 basados en heterociclo de 5 miembros. | |
| NO20052578L (no) | Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser | |
| MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| TW200621222A (en) | Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions | |
| TR200401316T4 (tr) | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler | |
| AU7548500A (en) | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents | |
| TNSN07440A1 (en) | Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung |